Banner - NPPA Connect

|Articles|March 23, 2023

Highlights from AAD 2023

Author(s)Lauren Buchanan, MA, Managing Editor

More than 300 innovative sessions, an engaging exhibit hall, and heartfelt networking—there was a lot to pack into AAD 2023! Here are the highlights.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

AbbVie Completes $10.9 Billion Apogee Acquisition, Adds Zumilokibart to AD Pipeline

ByShannon Heaning, Content Associate

September 3rd 2026

Joshua Arbesman, MD, on Balancing Photoprotection and Quality of Life in Melanoma Counseling

ByJoshua Arbesman, MD,Marie Bosslett, Assistant Editor

September 3rd 2026

The Evolving CSU Pipeline: Biologics, BTK Inhibitors, and Biomarker-Guided Care

ByNicholas Brownstone, MD,Marie Bosslett, Assistant Editor

September 2nd 2026

Journal Digest: September 2, 2026

ByMarie Bosslett, Assistant Editor

September 2nd 2026

Uncovering the Autoimmune Links & Systemic Impact of Chronic Spontaneous Urticaria

ByNicholas Brownstone, MD,Marie Bosslett, Assistant Editor

September 1st 2026

Latest CME

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

AbbVie Completes $10.9 Billion Apogee Acquisition, Adds Zumilokibart to AD Pipeline

10 Skin Cancer Exam Tips

The Evolving CSU Pipeline: Biologics, BTK Inhibitors, and Biomarker-Guided Care

Uncovering the Autoimmune Links & Systemic Impact of Chronic Spontaneous Urticaria

Taltz Plus Zepbound Show Durable Year 1 Efficacy in Psoriatic Disease